Loading organizations...
Key people at Deallus Consulting.
Deallus Consulting is a global life sciences consultancy based in London, United Kingdom, that provides competitive intelligence, market landscape analysis, and strategic advisory services to the pharmaceutical and biotechnology industries. The firm operates with a global workforce of over 110 employees, of which 80 percent hold advanced degrees and 35 percent hold doctorates, generating approximately £15 million in recent annual turnover. Private equity firm ArchiMed acquired a majority controlling stake in the consultancy to support its ongoing international expansion across the United States, Singapore, China, Japan, and India. The organization is currently led by Chief Executive Officer Pete Hempshall alongside Chief Commercial Officer Julie Munch Khan, following the earlier leadership of former chief executive Dr. Claudio D'Ambrosio. Deallus Consulting was established as a competitive intelligence firm and founded in 2004 by Richard Withers and Jonas Pedersen.
Key people at Deallus Consulting.
Deallus Consulting is a global strategic intelligence consultancy specializing in the life sciences sector, including pharma, biotech, and med-tech.[1][2][3] Founded in 2004 and headquartered in London, the firm employs over 200 professionals across offices in London, Los Angeles, New York, Shanghai, and Tokyo, with a mission to provide forward-thinking insights that enable clients to make strategic decisions, gain competitive advantages, and advance healthcare.[1][2][5] Its core services encompass opportunity and threat assessments, portfolio management, launch optimization, competitive intelligence, brand strategy, and market analysis, delivered through methodologies like primary research, workshops, and forecasting in therapeutic areas such as oncology, neuroscience, rare diseases, and vaccines.[1][2]
Deallus acts as an extension of clients' internal teams, offering peer-to-peer partnerships via its team of commercial scientists who blend scientific expertise with market realities.[2] This focus on strategic intelligence—rooted in competitive intelligence—helps life sciences companies navigate complex markets, refine strategies, and drive innovation, positioning Deallus as a key advisor to both global pharma leaders and emerging biotechs.[2][4][5]
Deallus was founded in 2004 in London as a competitive intelligence provider for the life sciences sector, deriving its name from a Celtic word meaning "intelligent," "understanding," and "wise."[1][3][4][5] Starting with a single office, it has evolved into a global firm with seven offices across four continents, growing to over 200 employees (with earlier milestones at 110-121 staff, 35% holding PhDs, and 80% with advanced degrees), while expanding services beyond CI to full strategic guidance.[1][2][5]
Key evolution includes building on its CI heritage to partner with top pharma companies and emerging biotechs, enhancing global presence in the US, China, Japan, and India for localized insights, and fostering a diverse team speaking over 25 languages.[2][4][5] No specific founding partners are named in available sources, but recent leadership additions like Peter Barschdorff as US Vice President underscore ongoing expansion.[3]
Deallus rides the wave of accelerating innovation in life sciences, where rapid advancements in biotech, personalized medicine, and AI-driven drug discovery demand agile strategic foresight amid regulatory pressures, supply chain disruptions, and competitive market entries.[1][2][5] Its timing aligns with the sector's evolution—post-2004 growth in emerging markets, vaccines, and rare diseases—providing intelligence that shapes clinical pathways, BD&L strategies, and portfolio prioritization when data overload and geopolitical shifts complicate decisions.[2]
Market forces like rising R&D costs, payer pressures, and global health threats favor Deallus's focus on competitive readiness and lifecycle management, influencing the ecosystem by empowering firms to define markets rather than react, as CI matures into a core strategic function.[1][4][5] This positions Deallus as a pivotal enabler for healthcare advancement, bridging science, commerce, and policy.
Deallus is poised for continued expansion, leveraging its 20+ years of CI expertise to deepen AI-integrated intelligence, therapeutic expansions (e.g., gene therapies, digital health), and emerging market penetration amid biotech funding rebounds and post-pandemic resilience.[2][5] Trends like precision medicine, value-based pricing, and cross-border collaborations will amplify demand for its global, data-driven strategies, potentially growing headcount and services into adjacent areas like med-tech AI.
As life sciences firms prioritize proactive market-shaping over reactive play, Deallus's role as a "wise" strategic partner will evolve, solidifying its influence in advancing patient outcomes through competitive edges—echoing its founding mission to deliver clarity in complexity.[4]
